QI
ACRS icon

QS Investors’s Aclaris Therapeutics ACRS Stock Holding History

QS Investors’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$643K Sell
36,600
-19,250
-34% -$437K 0.01% 633
2021
Q1 		$1.41M Buy
+55,850
New +$1.09M 0.02% 430

Other funds holding ACRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

QS Investors's ACRS Position: Q2 2021 in Review

QS Investors reduced its Aclaris Therapeutics (ACRS) stake by 34% in Q2 2021, selling an estimated $437K and leaving 36,600 shares worth $643K. The position accounts for 0.01% of the portfolio, ranked #633.

QS Investors first reported a position in ACRS in Q1 2021 and has held it in 2 quarters since. The position peaked at $1.41M in Q1 2021. 128 funds tracked by Wall St. Rank hold ACRS as of Q2 2021.

  • QS Investors held 36,600 shares of Aclaris Therapeutics worth $643K as of Q2 2021.
  • QS Investors sold 19,250 Aclaris Therapeutics shares in Q2 2021, an estimated $437K.
  • Aclaris Therapeutics made up 0.01% of QS Investors's portfolio in Q2 2021, its #633 holding.
  • QS Investors first reported a position in Aclaris Therapeutics in Q1 2021 and has held it in 2 quarters since.
  • QS Investors's Aclaris Therapeutics position peaked at $1.41M in Q1 2021.
  • 128 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2021.

Based on QS Investors's 13F filing for Q2 2021, filed 13 Aug 2021.